{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:37:54Z","timestamp":1782538674811,"version":"3.54.5"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007048","name":"EEA Grants and Norway Grants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0161kolstv\u00ed ml\u00e1de\u017ee a t\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1372\/2020"],"award-info":[{"award-number":["MUNI\/A\/1372\/2020"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0161kolstv\u00ed ml\u00e1de\u017ee a t\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1580\/2023"],"award-info":[{"award-number":["MUNI\/A\/1580\/2023"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116763","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:37:57Z","timestamp":1716824277000},"page":"116763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model"],"prefix":"10.1016","volume":"176","author":[{"given":"Katerina","family":"Horska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Drazanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Kuzminova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Amchova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hrickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-0799","authenticated-orcid":false,"given":"Jana","family":"Ruda-Kucerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-2124","authenticated-orcid":false,"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116763_bib1","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/nu12123883","article-title":"Exploring patterns of disturbed eating in psychosis: a scoping review","volume":"12","author":"Stogios","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2024.116763_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2024.116763_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis","volume":"78","author":"Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eurpsy.2018.07.004","volume":"54","author":"Stubbs","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.116763_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/acps.13266","article-title":"How and when to treat the most common adverse effects of antipsychotics: expert review from research to clinical practice","volume":"143","author":"Stahl","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.biopha.2024.116763_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jad.2021.08.023","article-title":"Clozapine induces metformin-resistant prediabetes\/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia","volume":"295","author":"Zhuo","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.biopha.2024.116763_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ebmental-2021-300291","article-title":"Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology","volume":"25","author":"Fitzgerald","year":"2022","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.biopha.2024.116763_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40267-021-00856-9","article-title":"Managing glucose-related adverse events of antipsychotics is worth the effort","volume":"37","author":"Fenton","year":"2021","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.biopha.2024.116763_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis","volume":"78","author":"Lee","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3803\/EnM.2020.934","article-title":"Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials","volume":"36","author":"Moon","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.biopha.2024.116763_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116763_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1815178","article-title":"The impact of incretin-based medications on lipid metabolism","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2024.116763_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2019.05.044","volume":"257","author":"Pozzi","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.biopha.2024.116763_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","article-title":"Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential","volume":"30","author":"Flintoff","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2024.116763_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.116763_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomized controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.biopha.2024.116763_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113830","article-title":"Effect of liraglutide 3.0 mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.biopha.2024.116763_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized double-blind placebo-controlled trial","author":"Whicher","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tem.2022.06.005","article-title":"GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?","volume":"33","author":"Horska","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1153648","article-title":"Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis","volume":"14","author":"Khaity","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.116763_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.biopha.2024.116763_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","article-title":"GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.biopha.2024.116763_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib32","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1152\/ajpendo.00309.2020","article-title":"GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia","volume":"319","author":"Medak","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2024.116763_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0269881120981377","article-title":"Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats","volume":"35","author":"Babic","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145713000862","article-title":"Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects","volume":"17","author":"Skrede","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib36","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/0269881115602490","article-title":"Antipsychotic-induced metabolic effects in the female rat: direct comparison between long-acting injections of risperidone and olanzapine","volume":"29","author":"Ersland","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","article-title":"Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain","volume":"25","author":"Fern\u00f8","year":"2015","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopha.2024.116763_bib39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/ijnp\/pyz012","article-title":"One-year treatment with Olanzapine depot in female rats: metabolic effects","volume":"22","author":"Ersland","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115214","article-title":"Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation","volume":"406","author":"Horska","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib41","article-title":"Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: untargeted proteomics approach in adipose tissue","volume":"2020","author":"Kucera","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/0269881117691466","article-title":"Depot risperidone-induced adverse metabolic alterations in female rats","volume":"31","author":"Horska","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2024.116763_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1467-789X.2006.00270.x","article-title":"The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review","volume":"8","author":"Klok","year":"2007","journal-title":"Obes. Rev."},{"key":"10.1016\/j.biopha.2024.116763_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"Muller","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.coph.2009.07.001","article-title":"FGFs and metabolism","volume":"9","author":"Kharitonenkov","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1538-7836.2004.00827.x","article-title":"Pleiotropic functions of plasminogen activator inhibitor-1","volume":"3","author":"Lijnen","year":"2005","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.biopha.2024.116763_bib48","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/bph.15178","article-title":"ARRIVE 2.0 and the british journal of pharmacology: updated guidance for 2020","volume":"177","author":"Lilley","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116763_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14565","article-title":"Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model","volume":"30","author":"Horska","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2024.116763_bib50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.pharep.2019.04.020","article-title":"Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats","volume":"71","author":"Drazanova","year":"2019","journal-title":"Pharmacol. Rep. PR"},{"key":"10.1016\/j.biopha.2024.116763_bib51","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2024.116763_bib52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/0192623315596857","article-title":"An investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in male Zucker diabetic fatty (ZDF) rats given dulaglutide by subcutaneous injection twice weekly for 13 weeks","volume":"43","author":"Usborne","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2024.116763_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.psyneuen.2018.03.021","article-title":"Leptin\/adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia","volume":"92","author":"Chen","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopha.2024.116763_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2022.856485","article-title":"Liraglutide lowers palmitoleate levels in type 2 diabetes. A post Hoc analysis of the LIRAFLAME RAndomized Placebo-controlled Trial","volume":"3","author":"Wretlind","year":"2022","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.biopha.2024.116763_bib56","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/s41598-022-06143-5","article-title":"Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt\/-catenin signaling pathway","volume":"12","author":"Khalifa","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116763_bib57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2024.116763_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.815456","article-title":"Understanding the effects of antipsychotics on appetite control","volume":"8","author":"Mukherjee","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2024.116763_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obes. Silver Spring Md"},{"key":"10.1016\/j.biopha.2024.116763_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40360-020-00427-0","article-title":"Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin","volume":"21","author":"Liu","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2024.116763_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.116763_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopha.2024.116763_bib63","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/biomedicines11051427","article-title":"Adipokines as clinically relevant therapeutic targets in obesity","volume":"11","author":"W\u00fcrfel","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.116763_bib64","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopha.2024.116763_bib65","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fendo.2018.00584","article-title":"Dissecting the physiology and pathophysiology of glucagon-like peptide-1","volume":"9","author":"Paternoster","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116763_bib66","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.116763_bib67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.psychres.2018.12.159","article-title":"High serum levels of FGF21 are decreased in bipolar mania patients during psychotropic medication treatment and are associated with increased metabolism disturbance","volume":"272","author":"Hu","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.biopha.2024.116763_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuropharm.2017.06.003","article-title":"Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats","volume":"123","author":"Horska","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2024.116763_bib69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.116763_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068652","volume":"13","author":"Sass","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2024.116763_bib71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/acps.13376","article-title":"Weight gain on antipsychotics\u2013A perfect storm of complex pathophysiology and psychopharmacology","volume":"144","author":"Ebdrup","year":"2021","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:10:46Z","timestamp":1781651446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":71,"alternative-id":["S0753332224006474"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116763","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116763"}}